Summary of findings 3. Methotrexate + infliximab compared to Infliximab +/‐ placebo for maintenance of remission in Crohn's disease.
| Methotrexate + infliximab compared to Infliximab +/‐ placebo for maintenance of remission in Crohn's disease | ||||||
| Patient or population: patients with maintenance of remission in Crohn's disease Settings: Outpatient Intervention: Methotrexate + infliximab Comparison: Infliximab +/‐ placebo | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Infliximab +/‐ placebo | Methotrexate + infliximab | |||||
| Proportion of patients maintaining remission Follow‐up: 36‐48 weeks | 535 per 10001 | 546 per 1000 (407 to 739) | RR 1.02 (0.76 to 1.38) | 145 (2 studies) | ⊕⊕⊝⊝ Low2,3 | |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Control group risk comes from control arm of study 2 Schröder 2006 is an open‐label trial 3 Sparse data (78 events)